Mechanisms of action and therapeutic efficacies of the lipophilic antimycobacterial agents clofazimine and bedaquiline

Journal of Antimicrobial Chemotherapy

Volumn 72, Issue 2, 2017, Pages 338-353

  Cholo, Moloko C ^a   Mothiba, Maborwa T ^a   Fourie, Bernard ^a   Anderson, Ronald ^a  

^a UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

BEDAQUILINE; CLOFAZIMINE; ANTIINFECTIVE AGENT; CARRIER PROTEIN; QUINOLINE DERIVATIVE; SURFACTANT;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL CELL; BIOACCUMULATION; DRUG EFFICACY; DRUG STRUCTURE; EUKARYOTIC CELL; HUMAN; NONHUMAN; PHARMACODYNAMICS; CHEMISTRY; DRUG EFFECTS; METABOLISM; MYCOBACTERIUM TUBERCULOSIS; TRANSPORT AT THE CELLULAR LEVEL; TREATMENT OUTCOME; TUBERCULOSIS;

ANTI-BACTERIAL AGENTS; BIOLOGICAL TRANSPORT; CLOFAZIMINE; DIARYLQUINOLINES; HUMANS; MEMBRANE TRANSPORT PROTEINS; MYCOBACTERIUM TUBERCULOSIS; SURFACE-ACTIVE AGENTS; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 85014519116     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkw426     Document Type: Article

References (188)

1. World Health Organization. Global Tuberculosis Report 2015. WHO, Geneva, 2015. http://www.who.int/tb/publications/global_report/en/.
2. Chahine EB, Karaoui LR, Mansour H. Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis. Ann Pharmacother 2014; 48: 107-15.
3. Zumla AI, Gillespie SH, Hoelscher M et al. New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects. Lancet 2014; 14: 327-40.
4. Brigden G, Hewison C, Varaine F. New developments in the treatment of drug-resistant tuberculosis: clinical utility of bedaquiline and delamanid. Infect Drug Resist 2015; 8: 367-78.
5. Upadhayaya RS, Vandavasi JK, Vasireddy NR et al. Design, synthesis, biological evaluation and molecular modelling studies of novel quinoline derivatives against Mycobacterium tuberculosis. Bioorg Med Chem 2009; 17: 2830-41.
6. Somoskovi A, Bruderer V, Hömke R et al. A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment. Eur Respir J 2015; 45: 554-7.
7. Sloan DJ, Lewis JM. Management of multidrug-resistant TB: novel treatments and their expansion to low resource settings. Trans R Soc Trop Med Hyg 2016; 110: 163-72.
8. Meintjes G. Management of drug-resistant TB in patients with HIV co-infection. J Int AIDS Soc 2014; 17: 19508.
9. Palmero D, González Montaner P, Cufré M et al. First series of patients with XDR and pre-XDR TB treated with regimens that included meropenem-clavulanate in Argentina. Arch Bronconeumol 2015; 51: e49-52.
10. Szumowski JD, Lynch JB. Profile of delamanid for the treatment of multidrug-resistant tuberculosis. Drug Des Devel Ther 2015; 9: 677-82.
11. Wong EB, Cohen KA, Bishai WR. Rising to the challenge: new therapies for tuberculosis. Trends Microbiol 2013; 21: 493-501.
12. Lessem E, Cox H, Daniels C et al. Access to new medications for the treatment of drug-resistant tuberculosis: patient, provider and community perspectives. Int J Infect Dis 2015; 32: 56-60.
13. Padayatchi N, Gopal M, Naidoo R et al. Clofazimine in the treatment of extensively drug-resistant tuberculosis with HIV coinfection in South Africa: a retrospective cohort study. J Antimicrob Chemother 2014; 69: 3103-7.
14. World Health Organization. Companion Handbook to theWHO Guidelines for the Programmatic Management of Drug-resistant Tuberculosis. Published online, November 2014. www.who.int/tb/publications/pmdt_ companionhandbook/en/.
15. Falzon D, Jaramillo E, Schünemann HJ et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; 38: 516-28.
16. Shim TS, Jo KW. Medical treatment of pulmonary multidrug-resistant tuberculosis. Infect Chemother 2013; 45: 367-74.
17. van Altena R, de Vries G, Haar CH et al. Highly successful treatment outcome of multidrug-resistant tuberculosis in the Netherlands, 2000-2009. Int J Tuberc Lung Dis 2015; 19: 406-12.
18. Dey T, Brigden G, Cox H et al. Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother 2013; 68: 284-93.
19. Dooley KE, Obuku EA, Durakovic N et al. World health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential? J Infect Dis 2013; 207: 1352-8.
20. Guglielmetti L, Le Dû D, Jachym M et al. Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort. Clin Infect Dis 2015; 60: 188-94.
21. Li K, Schurig-Briccio LA, Feng X et al. Multitarget drug discovery for tuberculosis and other infectious diseases. J Med Chem 2014; 57: 3126-39.
22. Clofazimine. http://www.drugbank.ca/drugs/DB00845.
23. Bedaquiline. http://www.drugbank.ca/drugs/DB08903.
24. Feng X, Zhu W, Schurig-Briccio LA et al. Antiinfectives targeting enzymes and the proton motive force. Proc Natl Acad Sci USA 2015; 112: E7073-82.
25. Barry VC, Belton JG, Conalty ML et al. A new series of phenazines (rimino-compounds) with high antituberculosis activity. Nature 1957; 179: 1013-5.
26. Reddy VM, O'Sullivan JF, Gangadharam PR. Antimycobacterial activities of riminophenazines. J Antimicrob Chemother 1999; 43: 615-23.
27. Nunn AJ, Rusen ID, van Deun A et al. Evaluation of a standardised treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomised controlled trial. Trials 2014; 15: 353.
28. Moodley R, Godec TR, STREAM Trial Team. Short-course treatment for multidrug-resistant tuberculosis: the STREAM trials. Eur Respir Rev 2016; 25: 29-35.
29. van Deun A, Maug AK, Salim MA et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am Respir Crit Care Med 2010; 182: 684-92.
30. Trébucq A, Schwoebel V, Kuaban C et al. Expanding shortened MDR-TB treatment: the West African experience. Int J Tuberc Lung Dis 2014; 18 Suppl 1, S15.
31. Franzblau SG, O'Sullivan JF. Structure-activity relationships of selected phenazines against Mycobacterium leprae in vitro. Antimicrob Agents Chemother 1988; 32: 1583-5.
32. Cholo MC, Steel HC, Fourie PB et al. Clofazimine: current status and future prospects. J Antimicrob Chemother 2012; 67: 290-8.
33. Funk RS, Krise JP. Cationic amphiphilic drugs cause a marked expansion of apparent lysosomal volume: implications for an intracellular distribution-based drug interaction. Mol Pharm 2012; 9: 1384-95.
34. Kazmi F, Hensley T, Pope C et al. Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells). Drug Metab Dispos 2013; 41: 897-905.
35. Lanoix JP, Lenaerts AJ, Neurmberger EL. Heterogeneous disease progression and treatment response in a C3HeB/FeJ mouse model of tuberculosis. Dis Model Mech 2015; 8: 603-10.
36. Franzblau SG, White KE, O'Sullivan JF. Structure-activity relationships of tetramethylpiperidine-substituted phenazines against Mycobacterium leprae in vitro. Antimicrob Agents Chemother 1989; 33: 2004-5.
37. Steel HC, Matlola NM, Anderson R. Inhibition of potassium transport and growth of mycobacteria exposed to clofazimine and B669 is associated with a calcium-independent increase in microbial phospholipase A2 activity. J Antimicrob Chemother 1999; 44: 209-16.
38. Matlola NM, Steel HC, Anderson R. Antimycobacterial action of B4128, a novel tetramethylpiperidyl-substituted phenazine. J Antimicrob Chemother 2001; 47: 199-202.
39. Zhang D, Liu Y, Zhang C et al. Synthesis and biological evaluation of novel 2-methoxypyridylamino-substituted riminophenazine derivatives as antituberculosis agents. Molecules 2014; 19: 4380-94.
40. Zhang D, Lu Y, Liu B et al. Identification of less lipophilic riminophenazine derivatives for the treatment of drug-resistant tuberculosis. J Med Chem 2012; 55: 8409-17.
41. Grosset JH, Tyagi S, Almeida DV et al. Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice. Am J Respir Crit Care Med 2013; 188: 608-12.
42. Verma RK, Germishuizen WA, Motheo MP et al. Inhaled microparticles containing clofazimine are efficacious in treatment of experimental tuberculosis in mice. Antimicrob Agents Chemother 2013; 57: 1050-2.
43. van Rensburg CE, Jooné GK, O'Sullivan JF et al. Antimicrobial activities of clofazimine and B669 are mediated by lysophospholipids. Antimicrob Agents Chemother 1992; 36: 2729-35.
44. De Bruyn EE, Steel HC, van Rensburg EJ et al. The riminophenazines, clofazimine and B669, inhibit potassiumtransport in Gram-positive bacteria by a lysophospholipid-dependent mechanism. J Antimicrob Chemother 1996; 38: 349-62.
45. Van Rensburg CE, van Straten AM. An in vitro investigation of the susceptibility of Enterococcus faecalis to clofazimine and B669. J Antimicrob Chemother 1994; 33: 356-8.
46. van Rensburg CE, Jooné GK, Sirgel FA et al. In vitro investigation of the antimicrobial activities of novel tetramethylpiperidine-substituted phenazines against Mycobacterium tuberculosis. Chemotherapy 2000; 46: 43-8.
47. Makgatho ME, Anderson R, O'Sullivan JF et al. Tetramethylpiperidinesubstituted phenazines as novel anti-plasmodial agents. Drug Dev Res 2000; 50: 195-202.
48. Datta G, Bera T. The effects of clofazimine, niclosamide and amphotericin B, on electron transport of Leishmania donovani promastigotes. Indian J Med Res 2000; 112: 15-20.
49. Barteselli A, Casagrande M, Basilico N et al. Clofazimine analogs with antileishmanial and antiplasmodial activity. Bioorg Med Chem 2015; 23: 55-65.
50. Bellera CL, Balcazar DE, Vanrell MC et al. Computer-guided drug repurposing: identification of trypanocidal activity of clofazimine, benipine and saquinavir. Eur J Med Chem 2015; 93: 338-48.
51. Tuvshintulga B, AbouLaila M, Davaasuren B et al. Clofazimine inhibits the growth of Babesia and Theileria parasites in vitro and in vivo. Antimicrob Agents Chemother 2016; 60: 2739-46.
52. Panic G, Vargas M, Scandale I et al. Activity profile of an FDA-approved compound library against Schistosoma mansoni. PLoS Negl Trop Dis 2015; 9: e0003962.
53. Robbins N, Spitzer M, Yu Tet al. An antifungal combination matrix identifies a rich pool of adjuvant molecules that enhance drug activity against diverse fungal pathogens. Cell Rep 2015; 13: 1481-92.
54. Singh S, Bouzinbi N, Chaturvedi V et al. In vitro evaluation of a new drug combination against clinical isolates belonging to the Mycobacterium abscessus complex. Clin Microbiol Infect 2014; 20: O1124-7.
55. Cariello PF, Kwak EJ, Abdel-Massih RC et al. Safety and tolerability of clofazimine as salvage therapy for atypical mycobacterial infection in solid organ transplant recipients. Transpl Infect Dis 2015; 17: 111-8.
56. Bennie CJ, To JL, Martin PA et al. In vitro interaction of some drug combinations to inhibit rapidly growing mycobacteria isolates from cats and dogs and these isolates' susceptibility to cefovecin and clofazimine. Aust Vet J 2015; 93: 40-5.
57. Ferro BE, Meletiadis J, Wattenberg M et al. Clofazimine prevents the regrowth of Mycobacterium abscessus and Mycobacterium avium type strains exposed to amikacin and clarithromycin. Antimicrob Agents Chemother 2015; 60: 1097-105.
58. Obregón-Henao A, Arnett KA, Henao-Tamayo M et al. Susceptibility of Mycobacterium abscessus to antimycobacterial drugs in preclinical models. Antimicrob Agents Chemother 2015; 59: 6904-12.
59. Roy K, Sil A, Das NK et al. Effectiveness and safety of clofazimine and pentoxifylline in type 2 lepra reaction: a double-blind, randomized, controlled study. Int J Dermatol 2015; 54: 1325-32.
60. Xu J, Lu Y, Fu L et al. In vitro and in vivo activity of clofazimine against Mycobacterium tuberculosis persisters. Int J Tuberc Lung Dis 2012; 16: 1119-25.
61. Cholo MC, BoshoffHI, Steel HC et al. Effects of clofazimine on potassium uptake by a Trk-deletion mutant of Mycobacterium tuberculosis. J Antimicrob Chemother 2006; 57: 79-84.
62. Mothiba MT, Anderson R, Fourie B et al. Effects of clofazimine on planktonic and biofilm growth of Mycobacterium tuberculosis and Mycobacterium smegmatis. J Glob Antimicrob Resist 2015; 3: 13-8.
63. Williams K, Minkowski A, Amoabeng O et al. Sterilizing activities of novel combinations lacking first-and second-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother 2012; 56: 3114-20.
64. Zhang Z, Li T, Qu G et al. In vitro synergistic activity of clofazimine and other antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis isolates. Int J Antimicrob Agents 2015; 45: 71-5.
65. Zou L, Liu M, Wang Y et al. Determination of in vitro synergy between linezolid and other antimicrobial agents against Mycobacterium tuberculosis isolates. Tuberculosis (Edinb) 2015; 95: 839-42.
66. López-Gavín A, Tudó G, Vergara A et al. In vitro activity against Mycobacterium tuberculosis of levofloxacin, moxifloxacin and UB-8902 in combination with clofazimine and pretomanid. Int J Antimicrob Agents 2015; 46: 582-5.
67. Irwin SM, Gruppo V, Brooks E et al. Limited activity of clofazimine as a single drug in a mouse model of tuberculosis exhibiting caseous necrotic granulomas. Antimicrob Agents Chemother 2014; 58: 4026-34.
68. Tyagi S, Ammerman NC, Li SYet al. Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis. Proc Natl Acad Sci USA 2015; 112: 869-74.
69. Zhang M, Sala C, Hartkoorn RC et al. Streptomycin-starved Mycobacterium tuberculosis 18b, a drug discovery tool for latent tuberculosis. Antimicrob Agents Chemother 2012; 56: 5782-9.
70. Yano T, Kassovska-Bratinova S, Teh JS et al. Reduction of clofazimine by mycobacterial type 2 NADH:quinone oxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen species. J Biol Chem 2011; 286: 10276-87.
71. Piccaro G, Poce G, Biava M et al. Activity of lipophilic and hydrophilic drugs against dormant and replicating Mycobacterium tuberculosis. J Antibiot 2015; 68: 711-4.
72. Grant SS, Kaufmann BB, Chand NS et al. Eradication of bacterial persisters with antibiotic-generated hydroxyl radicals. Proc Natl Acad Sci USA 2010; 109: 12147-52.
73. Lechartier B, Cole ST. Mode of action of clofazimine and combination therapy with benzothiazinones against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2015; 59: 4457-63.
74. Lu P, Heineke MH, Koul A et al. The cytochrome bd-type quinol oxidase is important for survival of Mycobacterium smegmatis under peroxide and antibiotic-induced stress. Sci Rep 2015; 5: 10333.
75. Nazarov PV, Lider VA. Mechanism of the membrane stabilizing action of vitamins K and E under conditions of chronic phenol poisoning in albino rats. Vopr Pitan 1996; 2: 11-4.
76. Lu Y, Zheng M, Wang B et al. Clofazimine analogs with efficacy against experimental tuberculosis and reduced potential for accumulation. Antimicrob Agents Chemother 2011; 55: 5185-93.
77. Steel HC, Cockeran R, Anderson R. Platelet-activating factor and lyso-PAF possess direct antimicrobial properties in vitro. APMIS 2002; 110: 158-64.
78. LaDow JE, Warnock DC, Hamill KM et al. Bicephalic amphiphile architecture affects antibacterial activity. Eur J Med Chem 2011; 46: 4219-26.
79. Kapoor R, Eimerman PR, Hardy JW et al. Efficacy of antimicrobial peptoids against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2011; 55: 3058-62.
80. Bhattacharyya D, Sen PC. The effect of binding of chlorpromazine and chloroquine to ion transporting ATPases. Mol Cell Biochem 1999; 198: 179-85.
81. Datiles MJ, Johnson EA, McCarty RE. Inhibition of the ATPase activity of the catalytic portion of ATP synthases by cationic amphiphiles. Biochim Biophys Acta 2008; 1777: 362-8.
82. Hong S, Pedersen PL. ATP synthase and the actions of inhibitors utilized to study its roles in human health, disease, and other scientific areas. Microbiol Mol Biol Rev 2008; 72: 590-641.
83. Te Brake LH, Russel FG, van den Heuvel JJ et al. Inhibitory potential of tuberculosis drugs on ATP-binding cassette drug transporters. Tuberculosis (Edinb) 2016; 96: 150-7.
84. Anderson R, Smit MJ. Clofazimine and B669 inhibit the proliferative responses and Na+, K+-adenosine triphosphatase activity of human lymphocytes by a lysophospholipid-dependent mechanism. Biochem Pharmacol 1993; 46: 2029-38.
85. Ren YR, Pan F, Parvez S et al. Clofazimine inhibits human Kv1.3 potassium channel by perturbing calcium oscillation in T lymphocytes. PLoS One 2008; 3: e4009.
86. Faouzi M, Starkus J, Penner R. State-dependent blocking mechanismof Kv1.3 channels by the antimycobacterial drug clofazimine. Br J Pharmacol 2015; 172: 5161-73.
87. Van Rensburg CE, van Staden AM, Anderson R. The riminophenazine agents clofazimine and B669 inhibit the proliferation of cancer cell lines in vitro by phospholipase A2-mediated oxidative and nonoxidative mechanisms. Cancer Res 1993; 53: 318-23.
88. Officioso A, Alzoubi K, Manna C et al. Clofazimine induced suicidal death of human erythrocytes. Cell Physiol Biochem 2015; 37: 331-41.
89. Yoon GS, Keswani RK, Sud S et al. Clofazimine biocrystal accumulation in macrophages upregulates IL-1RA production to induce a systemic antiinflammatory state. Antimicrob Agents Chemother 2016; 60: 3470-9.
90. Hwang TJ, Dotsenko S, Jafarov A et al. Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies. BMJ Open 2014; 4: e004143.
91. Aung KJ, Van Deun A, Declercq E et al. Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis 2014; 18: 1180-7.
92. Kuaban C, Noeske J, Rieder HL et al. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. Int J Tuberc Lung Dis 2015; 19: 517-24.
93. Piubello A, Harouna SH, Souleymane MB et al. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. Int J Tuberc Lung Dis 2014; 18: 1188-94.
94. Prideaux B, Via LE, Zimmerman MD, Eum S et al. The association between sterilizing activity and drug distribution into tuberculosis lesions. Nat Med 2015; 21: 1223-7.
95. Swanson R, Ammerman N, Ngcobo B et al. Clofazimine contributes sustained antimicrobial activity after treatment cessation in the mouse model of tuberculosis chemotherapy. Antimicrob Agents Chemother 2016; 60: 2864-9.
96. Kurbatova EV, Dalton T, Ershova J et al. Additional drug resistance of multidrug-resistant tuberculosis in patients in 9 countries. Emerg Infect Dis 2015; 21: 977-83.
97. Bloemberg GV, Keller PM, Stucki D et al. Acquired resistance to bedaquiline and delamanid in therapy for tuberculosis. N Engl J Med 2015; 20: 1986-8.
98. Pule CM, Sampson SL, Warren RM et al. Efflux pump inhibitors: targeting mycobacterial efflux systems to enhance TB therapy. J Antimicrob Chemother 2016; 71: 17-26.
99. Pym AS, Diacon AH, Tang SJ et al. Bedaquiline in the treatment of multidrug-and extensively drug-resistant tuberculosis. Eur Respir J 2016; 47: 564-74.
100. Horita Y, Doi N. Comparative study of the effects of antituberculosis drugs and antiretroviral drugs on cytochrome P450 3A4 and P-glycoprotein. Antimicrob Agents Chemother 2014; 58: 3168-76.
101. Svensson EM, Murray S, Karlsson MO et al. Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug. J Antimicrob Chemother 2015; 70: 1106-14.
102. Xu HB, Jiang RH, Xiao HP. Clofazimine in the treatment of multidrugresistant tuberculosis. Clin Microbiol Infect 2012; 18: 1104-10.
103. Tang S, Yao L, Hao X et al. Clofazimine for the treatment of multidrugresistant tuberculosis: prospective, multicenter, randomized controlled study in China. Clin Infect Dis 2015; 60: 1361-7.
104. Gopal M, Padayatchi N, Metcalfe JZ et al. Systematic review of clofazimine for the treatment of drug-resistant tuberculosis. Int J Tuberc Lung Dis 2013; 17: 1001-7.
105. Andries K, Villellas C, Coeck N et al. Acquired resistance of Mycobacterium tuberculosis to bedaquiline. PLoS One 2014; 9: e102135.
106. Gupta S, Cohen KA, Winglee K et al. Efflux inhibition with verapamil potentiates bedaquiline in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2014; 58: 574-6.
107. Hartkoorn RC, Uplekar S, Cole ST. Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2014; 58: 2979-81.
108. Koser CU, Javid B, Liddell K et al. Drug resistance mechanisms and tuberculosis drugs. Lancet 2015; 385: 305-7.
109. Zhang S, Chen J, Cui P et al. Identification of novel mutations associated with clofazimine resistance in Mycobacterium tuberculosis. J Antimicrob Chemother 2015; 70: 2507-10.
110. Baijnath S, Naiker S, Shobo A et al. Evidence for the presence of clofazimine and its distribution in the healthy mouse brain. J Mol Histol 2015; 46: 439-42.
111. Baik J, Stringer KA, Mane G et al. Multiscale distribution and bioaccumulation analysis of clofazimine reveals a massive immune systemmediated xenobiotic sequestration response. Antimicrob Agents Chemother 2013; 57: 1218-30.
112. Srikanth CH, Joshi P, Bikkasani AK et al. Bone distribution study of anti leprotic drug clofazimine in rat bone marrow cells by a sensitive reverse phase liquid chromatography method. J Chromatogr B Analyt Technol Biomed Life Sci 2014; 960: 82-6.
113. Swanson RV, Adamson J, Moodley C et al. Pharmacokinetics and pharmacodynamics of clofazimine in a mouse model of tuberculosis. Antimicrob Agents Chemother 2015; 59: 3042-51.
114. Baik J, Rosania GR. Molecular imaging of intracellular drugmembrane aggregate formation. Mol Pharm 2011; 8: 1742-9.
115. Baik J, Rosania GR. Macrophage sequester clofazimine in an intracellular liquid crystal-like supramolecular organization. PLoS One 2012; 7: e47494.
116. Keswani RK, Yoon GS, Sud S et al. A far-red fluorescent probe for flow cytometry and image-based functional studies of xenobiotic sequestering macrophages. Cytometry 2015; 87: 855-67.
117. Yoon GS, Sud S, Keswani RK et al. Phagocytosed clofazimine biocrystals can modulate innate immune signalling by inhibiting TNFa and boosting IL-1RA secretion. Mol Pharm 2015; 12: 2517-27.
118. Keswani RK, Baik J, Yeomans L et al. Chemical analysis of drug biocrystals: a role for counter ion transport pathways in intracellular drug disposition. Mol Pharm 2015; 12: 2528-36.
119. Worley MV, Estrada SJ. Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis. Pharmacotherapy 2014; 34: 1187-97.
120. Philley JV, Wallace RJ Jr, Benwill JL et al. Preliminary results of bedaquiline as salvage therapy for patients with nontuberculousmycobacterial lung disease. Chest 2015; 148: 499-506.
121. Diacon AH, Pym A, Grobusch MPet al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 2014; 371: 723-32.
122. Geffen N. Anything to stay alive: the challenges of a campaign for an experimental drug. Dev World Bioeth 2016; 16: 45-54.
123. Lessem E, Bernardo J, Reed C et al. Informed use of bedaquiline for tuberculosis. Lancet 2015; 385: 1724.
124. Mingote LR, Namutamba D, Apina F et al. The use of bedaquiline in regimens to treat drug-resistant and drug-susceptible tuberculosis: a perspective from tuberculosis-affected communities. Lancet 2015; 385: 477-9.
125. Bélard S, Heuvelings CC, Janssen S et al. Bedaquiline for the treatment of drug-resistant tuberculosis. Expert Rev Anti Infect Ther 2015; 13: 535-53.
126. Conradie F, Meintjes G, Hughes J et al. Clinical access to bedaquiline programme for the treatment of drug-resistant tuberculosis. S Afr Med J 2014; 104: 164-6.
127. Patel RV, Riyaz SD, Park SW. Bedaquiline: a new hope to treat multidrug-resistant tuberculosis. Curr Top Med Chem 2014; 14: 1866-74.
128. Udwadia ZF, Amale RA, Mullerpattan JB. Initial experience of bedaquiline use in a series of drug-resistant tuberculosis patients from India. Int J Tuberc Lung Dis 2014; 18: 1315-8.
129. Furin J, Brigden G, Lessem E et al. Global progress and challenges in implementing new medications for treating multidrug-resistant tuberculosis. Emerg Infect Dis 2016; 22: e151430.
130. Andries K, Verhasselt P, Guillemont J et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005; 307: 223-7.
131. Cole ST, Alzari PM. Microbiology. TB-a new target, a new drug. Science 2005; 307: 214-5.
132. Jain PP, Degani MS, Raju A et al. Identification of a novel class of quinolone-oxadiazole hybrids as anti-tuberculosis agents. Bioorg Med Chem Lett 2016; 26: 645-9.
133. Qiao CJ, Wang XK, Xie F et al. Asymmetric synthesis and absolute configuration assignment of a new type of bedaquiline analogue. Molecules 2015; 20: 22272-85.
134. Balemans W, Vranckx L, Lounis N et al. Novel antibiotics targeting respiratory ATP synthesis in Gram-positive pathogenic bacteria. Antimicrob Agents Chemother 2012; 56: 4131-9.
135. Jain PP, Degani MS, Raju A et al. Rational drug design based synthesis of novel arylquinolines as anti-tuberculosis agents. Bioorg Med Chem Lett 2013; 23: 6097-105.
136. Gelber R, Andries K, Paredes RM et al. The diarylquinoline R207910 is bactericidal against Mycobacterium leprae in mice at low dose and administered intermittently. Antimicrob Agents Chemother 2009; 53: 3989-91.
137. Raju RM, Raju SM, Zhao Y et al. Leveraging advances in tuberculosis diagnosis and treatment to address nontuberculous mycobacterial disease. Emerg Infect Dis 2016; 22: 365-9.
138. Wang H, Zhang X, Bai Yet al. Comparative efficacy and acceptability of five anti-tubercular drugs in treatment of multidrug resistant tuberculosis: a network meta-analysis. J Clin Bioinforma 2015; 5: 5. doi:10.1186/s13336-015-0020.
139. Segala E, SougakoffW, Nevejans-Chauffour A et al. New mutations in the mycobacterial ATP synthase: new insights into the binding of the diarylquinoline TMC207 to the ATP synthase C-ring structure. Antimicrob Agents Chemother 2012; 56: 2326-34.
140. Gold B, Roberts J, Ling Y et al. Rapid, semiquantitative assay to discriminate among compounds with activity against replicating or nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother 2015; 59: 6521-38.
141. Reddy VM, Einck L, Andries K et al. In vitro interactions between new antitubercular drug candidates SQ109 and TMC207. Antimicrob Agents Chemother 2010; 54: 2840-6.
142. Field SK. Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment? Ther Adv Chronic Dis 2015; 6: 170-84.
143. Tasneen R, Betoudji F, Tyagi S et al. Contribution of oxazolidinones to the efficacy of novel regimens containing bedaquiline and pretomanid in a mouse model of tuberculosis. Antimicrob Agents Chemother 2015; 60: 270-7.
144. Makarov V, Lechartier B, Zhang M et al. Towards a new combination therapy for tuberculosis with next generation benzothiazinones. EMBO Mol Med 2014; 6: 372-83.
145. Tasneen R, Li SY, Peloquin CA et al. Sterilizing activity of novel TMC207-and PA-824-containing regimens in a murine model of tuberculosis. Antimicrob Agents Chemother 2011; 55: 5485-92.
146. Wallis RS, Jakubiec W, Mitton-Fry M et al. Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide. PLoS One 2012; 7: e30479.
147. Ibrahim M, Truffot-Pernot C, Andries K et al. Sterilizing activity of R2079-10 (TMC207)-containing regimens in the murine model of tuberculosis. Am J Respir Crit Care Med 2009; 180: 553-7.
148. Dhillon J, Andries K, Phillips PJ et al. Bactericidal activity of the diarylquinoline TMC207 against Mycobacterium tuberculosis outside and within cells. Tuberculosis 2010; 90: 301-5.
149. Diacon AH, Dawson R, von Groote-Bidlingmaier F et al. Bactericidal activity of pyrazinamide and clofazimine alone and in combination with pretonamid and bedaquiline. Am J Respir Crit Care Med 2015; 191: 943-53.
150. Leibert E, Danckers M, Rom WN. New drugs to treat multidrugresistant tuberculosis: the case for bedaquiline. Ther Clin Risk Manag 2014; 10: 597-602.
151. Vocat A, Hartkoorn RC, Lechartier B et al. Bioluminescence for assessing drug potency against nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother 2015; 59: 4012-9.
152. Irwin SM, Prideaux B, Lyon ER et al. Bedaquiline and pyrazinamide treatment responses are affected by pulmonary lesion heterogeneity in Mycobacterium tuberculosis infected C3HeB/FeJ mice. ACS Infect Dis 2016; 2: 251-67.
153. Maloney PC, Kashket ER, Wilson TH. A proton motive force drives ATP synthesis in bacteria. Proc Natl Acad Sci USA 1974; 71: 3896-900.
154. Hicks DB, Liu J, Fujisawa M et al. F1F0-ATP synthases of alkaliphilic bacteria: lessons from their adaptations. Biochim Biophys Acta 2010; 1797: 1362-77.
155. Goulooze SC, Cohen AF, Rissmann R. Bedaquiline. Br J Clin Pharmacol 2015; 80: 182-4.
156. de Jonge MR, Koymans LH, Guillemont JE et al. A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910. Proteins 2007; 67: 971-80.
157. Koul A, Dendouga N, Vergauwen K et al. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat Chem Biol 2007; 3: 323-4.
158. Preiss L, Langer JD, YildizÖ et al. Structure of the mycobacterial ATP synthase Fo rotor ring in complex with the anti-TB drug bedaquiline. Sci Adv 2015; 1: e1500106.
159. Koul A, Vranckx L, Dhar N et al. Delayed bactericidal response of Mycobacterium tuberculosis to bedaquiline involves remodelling of bacterial metabolism. Nat Commun 2014; 5: 3369.
160. Hards K, Robson JR, Berney M et al. Bactericidal mode of action of bedaquiline. J Antimicrob Chemother 2015; 70: 2028-37.
161. Berney M, Hartman TE, Jacobs WR Jr. A Mycobacterium tuberculosis cytochrome bd oxidase mutant is hypersensitive to bedaquiline. MBio 2014; 5: e01275-14.
162. Lamprecht DA, Finin PM, Rahman MA et al. Turning the respiratory flexibility of Mycobacterium tuberculosis against itself. Nat Commun 2016; 7: 12393: doi:10.1038.
163. Pethe K, Bifani P, Jang J et al. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. Nat Med 2013; 19: 1157-60.
164. Van Rensburg CEJ, Anderson R, O'Sullivan JF. Riminophenazine compounds: pharmacology and antineoplastic potential. Crit Rev Oncol Hematol 1997; 25: 55-67.
165. Fiorillo M, Lamb R, Tanawitz HB et al. Bedaquiline, an FDA-approved antibiotic inhibits mitochondrial function and potently blocks the proliferative expansion of stem-like cancer cells (CSCs). Aging; 8: 1-15.
166. Zaccagnino A, Manago A, Leanza L et al. Tumor-reducing effect of the clinically used drug clofazimine in a SCID mouse model of pancreatic ductal adenocarcinoma. Oncotarget 2016; doi:10.18632/oncotarget. 11299.
167. Diacon AH, Pym A, Grobusch M et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009; 360: 2397-405.
168. Diacon AH, Dawson R, Van Groote-Bidlingmaier F et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide and moxifloxacin combinations: a randomised trial. Lancet 2012; 380: 986-93.
169. Ndjeka N, Conradie F, Schnippel K et al. Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis. Int J Tuberc Lung Dis 2015; 19: 979-85.
170. Svensson EM, Dooley KE, Karlsson MO. Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection. Antimicrob Agents Chemother 2014; 58: 6406-12.
171. Pandie M, Wiesner L, McIlleron H et al. Drug-drug interactions between bedaquiline and the antiretrovirals lopinavir/ritonavir and nevirapine in HIV-infected patients with drug-resistant TB. J Antimicrob Chemother 2016; 71: 1037-40.
172. Hervé C, Bergot E, Veziris N et al. Tuberculosis in 2015: from diagnosis to the detection of multi-resistant cases. Rev Mal Respir 2015; 32: 784-90.
173. South African Department of Health. Introduction of New Drugs and Drug Regimens for the Management of Drug Resistant Tuberculosis in South Africa: Policy Framework Version 1.1: June 2015.
174. Torrea G, Coeck N, Desmaretz C et al. Bedaquiline susceptibility testing of Mycobacterium tuberculosis in an automated liquid culture system. J Antimicrob Chemother 2015; 70: 2300-5.
175. Keller PM, Hömke R, Ritter C et al. Determination of MIC distribution and epidemiological cut offvalues for bedaquiline and delamanid in Mycobacterium tuberculosis using the MGIT 960 system equipped with TB eXiST. Antimicrobial Agents Chemother 2015; 59: 4352-5.
176. Kakkar AK, Dahiya N. Bedaquiline for the treatment of resistant tuberculosis: promises and pitfalls. Tuberculosis 2014; 94: 357-62.
177. Huitric E, Verhasselt P, Koul A et al. Rates and mechanisms of resistance development in Mycobacterium tuberculosis to a novel diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother 2010; 54: 1022-8.
178. Grossman TH, Shoen CM, Jones SM et al. The efflux pump inhibitor timcodar improves the potency of antimycobacterial agents. Antimicrob Agents Chemother 2015; 59: 1534-41.
179. Srikrishna G, Gupta S, Dooley KE et al. Can the addition of verapamil to bedaquiline-containing regimens improve tuberculosis treatment outcomes? A novel approach to optimizing TB treatment. Future Microbiol 2015; 10: 1257-60.
180. Petrella S, Cambau E, Chauffour A et al. Genetic basis for natural and acquired resistance to the diarylquinoline R207910 in mycobacteria. Antimicrob Agents Chemother 2006; 50: 2853-6.
181. Mitchison D, Davies G. The chemotherapy of tuberculosis: past, present and future. Int J Tuberc Lung Dis 2012; 16: 724-32.
182. Gideon HP, Phuah JY, Myers AJ et al. Variability in tuberculosis granuloma T cell responses exists, but a balance of pro-and antiinflammatory cytokines is associated with sterilization. PLoS Pathog 2015; 11: e1004603.
183. Alffenaar JW, Bolhuis M, van Hateren K et al. Determination of bedaquiline in human serum using liquid chromatography-tandem mass spectrometry. Antimicrob Agents Chemother 2015; 59: 5675-80.
184. Akkerman O, Odish OF, Bolhuis MS et al. Pharmacokinetics of bedaquiline in cerebrospinal fluid and serum in multidrug-resistant tuberculous meningitis. Clin Infect Dis 2016; 62: 523-4.
185. Nau R, Sörgel F, Eiffert H. Penetration of drugs through the bloodcerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev 2010; 23: 858-83.
186. Winter H, Egizi E, Murray S et al. Evaluation of the pharmacokinetic interaction between repeated doses of rifapentine or rifampin and a single dose of bedaquiline in healthy adult subjects. Antimicrob Agents Chemother 2015; 59: 1219-24.
187. Kwon YS, Koh WJ. Synthetic investigational new drugs for the treatment of tuberculosis. Expert Opin Investig Drugs 2016; 25: 183-93.
188. Pontali E, Sotgiu G, D'Ambrosio L et al. Bedaquiline and multidrugresistant tuberculosis: a systematic and critical analysis of the evidence. Eur Respir J 2016; 47: 394-402.